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Background: The practice of traditional Chinese medicine (TCM) has a profound history in many Asian countries.
TCM syndrome is a set of characteristic physical signs and symptoms shared by a group of patients. Syndrome
diagnosis and treatment assignment according to the identified TCM syndrome is a long-held practice of Chinese
medicine. Owing to its distinctive way of interpreting illness and administering care, medical practitioners not well
educated in TCM theories and practices are generally incapable of giving out prescriptions for Chinese patent drugs.
Currently, the existence of a multitude of Chinese patent drugs marked with largely identical indications is further
complicating this situation.
Methods: In this multicenter, randomized, controlled, double-blind, double-dummy clinical trial, in which we will
use the comparative effectiveness research method, we will compare the efficacy of two commonly used Chinese
patent medicines for angina patients diagnosed with qi deficiency and blood stasis syndrome. A total of 160 patients
will be recruited and randomly assigned to receive either (1) QiShenYiQi dripping pills, Tongxinluo placebo and routine
medication or (2) Tongxinluo capsules, QiShenYiQi placebo and routine medication. These treatment regimens will be
carried out for 4 weeks, followed by a 10-day washout period and a 4-week crossover phase in which the treatments in
the two patient groups will be exchanged. Patients will be allowed to choose symptoms that matter most to them and
will be grouped accordingly. Patient-reported outcomes such as the Seattle Angina Questionnaire score and the 15-point
Likert scale score will be measured and reported. The minimally clinical important difference will be calculated and used
for efficacy assessment, and correspondence analysis will be performed to identify the best indications for each drug.
Discussion: The goal of the study is to establish a methodology for the precise identification of the characteristic
indications for which a Chinese patent drug is most effective. The findings of this study will inform the practicality of the
proposed evaluation method.
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Traditional Chinese medicine interpretation of angina and
therapeutic rules
Syndrome differentiation, also termed pattern diagnosis
(Bian Zheng in Chinese pinyin), is one of the kernel the-
ories of traditional Chinese medicine (TCM). The TCM
syndrome, or Zheng, is a characteristic profile of clinical
signs and symptoms manifested by a group of patients.
The clinical efficacy of Chinese medicine relies heavily
on the correct diagnosis of a specific TCM syndrome.
According to the 2002 Guidelines for Clinical Research
of Chinese Medicine (new drug) [1] released by the
Chinese Food and Drug Administration patients with
angina pectoris can be diagnosed on the basis of any one
of the following eight TCM patterns: (1) qi deficiency
and blood stasis syndrome, (2) heart blood stasis ob-
struction syndrome, (3) qi stagnation and blood stasis
syndrome, (4) syndrome of phlegm obstruction in the
heart vessel, (5) syndrome of congealing yin cold, (6)
dual-deficiency of qi and yin syndrome, (7) heart and
kidney yin deficiency syndrome and (8) yang qi debilita-
tion syndrome. Among these criteria, the qi deficiency
and blood stasis syndrome is most typically observed in
Chinese angina patients.
For the management of angina pectoris patients with
qi deficiency and blood stasis syndrome, herbal remedies
intended to invigorate qi, activate blood circulation and
transform stasis will be administered. The main function
of the herbal remedy is to improve clinical signs and
symptoms of the patients.
Comparative effectiveness research and traditional
Chinese medicine
The concept of comparative effectiveness research (CER)
was initiated in the 1990s by Mark Boutin, the deputy
executive president and chief operating officer of the US
National Health Council [2]. In the years that followed,
CER has been used to aid public health policy-making and
introduced into the field of clinical research in a number
of countries [3]. In May 2011, Claudia M Witt (Institute
of Social Medicine, Epidemiology and Health Economics,
Charité University Medical Center, Berlin, Germany) pro-
posed introducing CER techniques into TCM research at
the sixth annual meeting of the International Society of
Complementary Medicine Research [4].
Efficacy evaluation based on patient-reported outcomes
A patient-reported outcome (PRO) is a report directly
from the patient, without influences from doctors or
others, about how they function or feel in relation to
their health status and the treatment they are receiving
[5]. The PRO measurement tools are developed to pro-
vide insights from the patient’s perspective regarding the
impact of therapeutic interventions on their health.Patient-important outcomes (PIOs) are a selection of
outcome measures that are considered most relevant to
the patients. Examples of PIOs include pain, fatigue,
quality of life and death. Efforts to assess PIOs for a par-
ticular disease or condition and to promote the use of
PIOs in clinical research settings facilitate effective inter-
pretation of the results by emphasizing the evaluation of
treatment effectiveness. The integration of PIOs and
PROs into Comparative Effectiveness Research could be
a useful tool for the assessment of outcomes requiring
patients’ subjective perceptions and judgments, such
as consumer satisfaction and health-related quality of
life [6].
Minimal clinically important differences and patient-reported
outcome measurements
Minimal clinically important differences (MCIDs) are
self-perceived scores that signify clinically significant im-
provements in PROs that can be used to identify the
minimal changes in a specific aspect of a patient’s health
[7], and it is believed to reflect the smallest change in
the PRO evaluations of a clinical intervention that is
meaningful to the patient.
Distribution-based methods for the determination of
MCIDs have been widely used and can be subdivided
into the effect size (ES) and the standard error of meas-
urement (SEM). The latter measurement is particularly
recommended for its relative independence from sample
source and stability across different studies [8,9]. In our
present study, changes in PROs will be calculated using
the SEM, which will represent patients’ self-reported im-
provements in symptoms or health-related function.
Traditional Chinese medicine for angina pectoris due to
coronary heart disease
Angina pectoris is one of the most common symptoms
of coronary heart disease (CHD) and afflicts a large por-
tion of CHD patients. It has been found over the course
of years of clinical practice that TCM is effective in
treating angina. Because the qi deficiency and blood sta-
sis syndrome together have been identified as a major
TCM syndrome among patients with angina, in this
CER study we will select two Chinese patent drugs most
frequently used for treating angina patients diagnosed
with this common syndrome. The patent drugs to be
compared are QiShenYiQi (QSYQ) dripping pills (Tasly
Pharmaceutical Co Ltd, Tianjin, China) and Tongxin-
luo (TXL) capsules (Yiling Pharmaceutical Co Ltd,
Shijiazhuang City, China). QSYQ pills are composed
mainly of Radix Astragali, Radix Salvia miltiorrhiza,
Radix Notoginseng and Lignum Dalbergia Odorifera.
TXL capsules are an herbal mixture of Radix Ginseng,
Hirudo, Quan Xie Eupolyphaga seu Steleophaga, Scol-
opendra, Periostracum Cicadae, Radix Paeoniae rubra,
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frankincense, Semen Ziziphi spinosae and borneol.Objectives
We are conducting a multicenter, randomized, controlled,
double-blind, double-dummy clinical trial to compare the
effectiveness of two Chinese patent medicines for angina
patients diagnosed with qi deficiency and blood stasis
syndrome. The ultimate goal is to test the proposed
methodology for the individualized evaluation of the
therapeutic effects of Chinese patent drugs and for dis-
tinguishing between drugs targeting a multitude of
similar indications.
To fulfill these objectives in our present study, we
highlight the introduction of trial participants’ thera-
peutic needs and willingness in terms of group alloca-
tion and the use of CER methodology. Specifically
before being entered into the randomization process,
all eligible participants with qi deficiency and bloodFigure 1 Study flowchart. CA, Correspondence analysis; CER, Comparative
PIO, Patient-important outcome; SAQ, Seattle Angina Questionnaire.stasis syndrome will first be allowed to choose from
among four prespecified groups of symptoms which
they would most like to be addressed. The outcomes
for these symptoms are considered PIOs and will be
assessed using PRO instruments. Furthermore, we will
test the use of the CER method to compare the cura-
tive effects of QSYQ dripping pills and TXL capsules,
two widely used Chinese patent medicines for angina
patients with qi deficiency and blood stasis syndrome.
By analyzing and comparing the effects of the two
drugs for each symptom group, we aim to summarize
the characteristics of the drugs’ curative effects and
identify the best targeted indications for each drug.Methods
Study design
We will conduct a multicenter, randomized, crossover,
double-blind, double-dummy clinical trial. A flowchart
of the study protocol is shown in Figure 1.effectiveness research; MCID, Minimal clinically important difference;
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This study has been approved by the medical ethics
committee of Tianjin University of Traditional Chinese
Medicine (registration number TJUTCM-EC20130004).
Setting
Participants will be recruited simultaneously at the car-
diology departments of four hospitals in Tianjin City in
mainland China.
Participant recruitment
Potentially eligible angina patients will be provided with
general information regarding the trial, the objectives of
the research and the rights and obligations of the partici-
pants at the first visit. Those who are willing to participate
will be asked to give their informed consent to participate
before being entered into the screening process. Partici-
pants will then be included or excluded according to the
predefined inclusion and exclusion criteria.
Diagnostic criteria for traditional Chinese medicine
patterns
According to the 2002 Guidelines for Clinical Research
of Chinese Medicine (new drug), any patient presenting
with the primary symptoms mentioned below and at
least one of the secondary symptoms, with typical
tongue and pulse presentations, will be diagnosed with
qi deficiency and blood stasis syndrome. Primary symp-
toms include chest pain and chest tightness. Secondary
symptoms include shortness of breath, fatigue, palpita-
tions and/or spontaneous perspiration. .
Inclusion criteria
1. Patients ages 40 to 75 years old
2. Provision of signed informed consent
3. Diagnosis of angina pectoris due to CHD (stable
angina, New York Heart Association (NYHA)
classes I to III)
4. TCM pattern diagnosis of qi deficiency and blood stasis
Exclusion criteria
1. Patients younger than 40 or older than 75 years old
2. Diagnosis of NYHA class IV CHD
3. Uncontrolled NYHA class III hypertension (systolic
blood pressure ≥180 mmHg and/or diastolic blood
pressure ≥110 mmHg)
4. Presence of severe arrhythmia
5. Patients with serious primary hepatic, renal,
hematologic or mental illness and those with
malignant tumors
6. Presence of active peptic ulcers and other
hemorrhagic diseases7. Pregnancy or lactation
8. Patients with other complications who should not be
included in the trial as adjudged by the recruiting
personnel
9. Patients with an allergic constitution or a history of
allergy to the investigational drug
10.Participation in another clinical trial, either currently
or within the past 3 months
Exclusion criteria
1. Incidence of serious adverse events.
2. Major design flaws or serious deviation from
research protocol
3. Cancellation of the study by administrative
authorities
Patient grouping and treatment allocation
Using stratified and blocked randomization, we will first
categorize eligible participants into four groups on the
basis of their varied choice of secondary symptoms to be
addressed, and then we will randomly assign them to one
of the two treatment arms at a ratio of 1:1. To minimize
imbalances across groups, gender will also be used as a
stratification factor. The random number sequence will be
generated by a third-party statistician using SAS version
9.1 software (SAS Institute, Cary, NC, USA).
The four symptom combination groups, each repre-
senting the signs a patient most wishes to bring under
control, were formed according to the characteristic
physical manifestations of the qi deficiency and blood
stasis syndrome defined in the 2002 Guidelines for
Clinical Research of Chinese Medicine (new drug). The
grouping criteria for patients with varying therapeutic
needs resulted in the following four symptom combin-
ation groups:
1. Combination 1: chest pain + chest tightness + shortness
of breath
2. Combination 2: chest pain + chest tightness + fatigue
3. Combination 3: chest pain + chest tightness +
palpitations
4. Combination 4: chest pain + chest tightness +
spontaneous perspiration
Sample size calculation
Sample size estimation is based on the results of a pilot
study that showed the difference in changes in Seattle
Angina Questionnaire (SAQ) scores of 2 ± 2.5 between
the group receiving QSYQ dripping pills and the group tak-
ing TXL capsules. Assuming a two-sided P-value of 0.05,
90% power and calculating for a dropout rate of 20%, one
would need to have approximately 160 patients with 80 in
each treatment group. We used the PAST software program
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past/) [10]. Therefore, we plan to recruit 40 patients for each
of the four symptom combinations, from among whom 20
will be assigned to treatment arm A (QSYQ) and 20 to
treatment arm B (TXL). In all, 160 patients will be recruited.
Randomization
Randomization of the trial participants will be com-
pleted using an independent data center using an inter-
active voice response system.
Blinding and allocation concealment
The test drug will be coded and placed in indistinguish-
able containers by specially assigned personnel who will
not participate in other procedures in the trial. Drug as-
signments will be enclosed in sealed, opaque envelopes
and kept confidential by the trial management board.
Thus, the patients, clinicians, participating nurses, trial
coordinators, outcome assessors and statisticians will be
blinded to treatment assignment.
Baseline assessment
General information about the patient’s gender, age and
heart function will be collected and assessed after eligi-
bility screening to ensure balanced baseline values.
Assignment of interventions
In this study, we adopt a crossover design which involves
three key phases: a 4-week treatment period, a 10-day
washout period and the crossover of treatment for an-
other 4 weeks:
1. The first treatment period (4 weeks): A total of 160
participants will be randomly assigned to receive
treatment A or treatment B for 4 weeks.
1.a. Treatment A: QSYQ dripping pills + TXL placebo +
routine medication
1.b. Treatment B: TXL capsules + QSYQ placebo +
routine medication
2. Washout phase (10 days): After the first round of
treatment, patients in both groups will receiveFigure 2 Calculation of the M value. SAQ, Seattle Assessment QuestionnQSYQ placebo and TXL placebo plus routine
medication for 10 days.
3. Crossover of treatments (4 weeks): In this stage,
patients formerly assigned to treatment A will be
switched to treatment B and those assigned to
treatment B will be switched to treatment A.
Routine medication
Routine medications will include aspirin, angiotensin-
converting enzyme inhibitors or angiotensin receptor
blockers, β-receptor blockers, statins and nitrates.
Concomitant medications
1. Dihydropyridines and diuretics
2. Antidiabetic drugs
3. Digoxin and diuretics
Measurement tools and time of data capture
The SAQ and 15-point Likert scale scores will be used to
collect PROs immediately following the first treatment
period and the crossover treatment period. The minimal
clinically important differences (MCIDs) of the SAQ and
the Likert scale scores at these two time points will be cal-
culated for efficacy evaluation and comparison.
Efficacy assessment tools
1. MCID calculation [11]: The MCID value will be
calculated using the SEM method and following the
steps outlined below:
1.a. Calculation of M (M0 and M1) (Figure 2):
1.a.i. Find patients receiving treatment A (or treatment
B) whose self-reported Likert scores are within
the range of +2 to +3.
1.a.ii. Collect the corresponding SAQ score of these
patients, use X1 to refer to it and calculate the
mean value X —ð Þ1.
1.a.iii. Find patients receiving Treatment A (or
Treatment B) whose self-reported Likert scores
are within the range of 0 to +1.aire.




Four groups of patients categorized
using the efficacy assessment tool
Group 1 Group 2 Group 3 Group 4
Combination 1 AB1/N A1/N B1/N ab1/N
Combination 2 AB2/N A2/N B2/N ab2/N
Combination 3 AB3/N A3/N B3/N ab3/N
Combination 4 AB4/N A4/N B4/N ab4/N
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to refer to it and calculate the mean value X0
1.a.v. M0 = X0-X —ð Þ0
1.a.vi. M1 = X1-X —ð Þ1

















n:sample size; r:the reliability coefficient of SAQ
3. Calculation of MCID We will calculate the MCIDs
for treatment A (referred to as MCID1) and
treatment B (referred to as MCID2) during the first
treatment period and for treatment A (referred to as
MCID3) and treatment B (referred to as MCID4)
during the crossover period.
MCID, Minimal clinically important difference; SEM,





4. Individualized efficacy evaluation upon the first
round of treatment: Treatment interventions will be
defined as either effective or ineffective by
comparison of the patient’s personal SAQ score with
the calculated MCID value.
4.a. Treatment A will be defined as effective if a patient
receiving it has a SAQ score greater than the
MCID1 score.
4.b. Treatment B will be defined as effective if a patient
receiving it has a SAQ score greater than the
MCID2 score.
4.c. A treatment will be adjudged ineffective if a patient
receiving it reports a SAQ score lower than the
corresponding MCID value (MCID1 or MCID2).
5. Individualized efficacy evaluation upon crossover
of treatment: Because of the complexity of the
study design, all the patients will be categorized
into four groups by using the following assessment
tools:
5.a. Group 1: Both treatments A and B are effective for
patients in this group:
5.a.i. For patients who first receive treatment A and
then treatment B, the first SAQ score >MCID1
and the second SAQ score >MCID4
5.a.ii. For patients who first receive treatment B and
then treatment A, the first SAQ score >MCID2
and the second SAQ score >MCID35.b. Group 2: Treatment A is effective and treatment B
is ineffective for patients in this group:
5.b.i. For patients who first receive treatment A and
then treatment B, the first SAQ score >MCID1
and the second SAQ score <MCID4
5.b.ii. For patients who first receive treatment B and
then treatment A, the first SAQ score >MCID2
and the second SAQ score <MCID3.
5.c. Group 3: Treatment B is effective and treatment A
is ineffective for patients in this group:
5.c.i. For patients who first receive treatment A and
then treatment B, the first SAQ score <MCID1
and the second SAQ score >MCID4
5.c.ii. For patients who first receive treatment B and
then treatment A, the first SAQ score <MCID2
and the second SAQ score >MCID3
5.d. Group 4: Both treatments A and B are ineffective
for patients in this group:
5.d.i. For patients who first receive treatment A and
then treatment B, the first SAQ score <MCID1
and the second SAQ score <MCID4
5.d.ii. For patients who first receive treatment B and
then treatment A, the first SAQ score <MCID2
and the second SAQ score <MCID3
Statistical analysis
Test for baseline balance
Baseline data will be analyzed using an independent
t-test, analysis of variance and the χ2 test to check
whether the randomization has resulted in equal distri-
butions of known confounding factors, such as age, gen-
der, living status and education level.
Comparison of the curative effects of treatment A and
treatment B on symptoms related to angina
Table 1 shows how the intervention treatments work for
patients presenting with each of the four symptom
combinations.
AB1 to AB4 refer to the number of patients requiring
treatment for symptom combinations 1 to 4 and for
whom both QSYQ and TXL are effective. A1 to A4 refer
to the number of patients requiring treatment for
symptom combinations 1 to 4 and for whom QSYQ is
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number of patients requiring treatment for symptom
combinations 1 to 4 and for whom QSYQ is ineffective
and TXL is effective. ab1 to ab4 refer to the number of
patients requiring treatment for symptom combinations
1 to 4 and for whom both QSYQ and TXL are ineffect-
ive N refers to the total number of patients who fall
within each symptom combination group, which is
planned to be 40.
Table 2 shows how the intervention treatments will work
for patients presenting with two or more of the four symp-
tom combinations. All possible symptom combinations are
presented in the table. The total number of patients acting
as the denominator increases with the number of symptom
combinations involved.
Correspondence analysis
Correspondence analysis (CA) is a statistical technique
designed to demonstrate or summarize a set of data in
two-dimensional graphical form, typically a biplot, which
can help in the detection of the structural relationships
among the variables contained in the rows and columns
of a contingency table. In this study, SPSS version 16.0
software (SPSS Inc, Chicago, IL, USA) will be used to
perform CA of the data in Tables 1 and 2. Statistical
analysis will follow the steps listed below:
1. Specify the value of dimensions.
2. For both tables, the number of dimensions will be
set at two.
3. Production of a CA plot.
The biplot is a matrix of joint plots of the row and col-
umn points. In the biplot, types of symptom combinations
and different outcome groups are shown as points. The
abscissa value is determined by the score of the first di-
mension of symptom combinations and outcome groups.Table 2 Efficacy assessment by category of multiple symptom
Multiple symptom
combinations
Four groups of patien
Group 1 Gro
Combination (1 + 2) (AB1 + AB2)/2 N (A1 +
Combination (1 + 3) (AB1 + AB3)/2 N (A1 +
Combination (1 + 4) (AB1 + AB4)/2 N (A1 +
Combination (2 + 3) (AB2 + AB3)/2 N (A2 +
Combination (2 + 4) (AB2 + AB4)/2 N (A2 +
Combination (3 + 4) (AB3 + AB4)/2 N (A3 +
Combination (1 + 2 + 3) (AB1 + AB2 + AB3)/3 N (A1 + A2
Combination (1 + 2 + 4) (AB1 + AB2 + AB4)/3 N (A1 + A2
Combination (1 + 3 + 4) (AB1 + AB3 + AB4)/3 N (A1 + A3
Combination (2 + 3 + 4) (AB2 + AB3 + AB4)/3 N (A2 + A3
Combination (1 + 2 + 3 + 4) (AB1 + AB2 + AB3 + AB4)/4 N (A1 + A2 +The ordinate value is the score of the second dimension
of symptom combinations and outcome groups.
4. Calculation of “D (A–B)” refers to the relative
distance between point A and point B in the biplot.
“a1” and “b1” refer to the abscissa values of point A
and point B. “a2” and “b2” refer to the ordinate
values of point A and point B.
5. The relative distance between points displayed in the
CA plot will be summarized in a table. As
prespecified, the pair of symptom combinations and
outcome types with the nearest relative distance will
signify the most significant correlation. The
characteristic indications for which the patent drug
is most effective will be found upon careful
screening.
6. The value of relative distance between two points in
the biplot will be calculated using the following
formula.
D A‐Bð Þ ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
a1 ‐ b1ð Þ2 þ a2−b2ð Þ2
q
Safety
Adverse events (AEs) and adverse drug reactions (ADRs)
will be monitored and reported throughout the study.
The incidence of AEs and ADRs will be compared be-
tween groups using the χ2 test with the level of signifi-
cance set at P < 0.05.
Drug management
The central drug administrator will be responsible for
drug distribution to and reclamation from each center.
Drug administrators at each center will hand out test
drugs to the patients and reclaim unused drugs. A drug
management log book will be kept.combinations
ts categorized using the efficacy assessment tool
up 2 Group 3 Group 4
A2)/2 N (B1 + B2)/2 N (ab1 + ab2)/2 N
A3)/2 N (B1 + B3)/2 N (ab1 + ab3)/2 N
A4)/2 N (B1 + B4)/2 N (ab1 + ab4)/2 N
A3)/2 N (B2 + B3)/2 N (ab2 + ab3)/2 N
A4)/2 N (B2 + B4)/2 N (ab2 + ab4)/2 N
A4)/2 N (B3 + B4)/2 N (ab3 + ab4)/2 N
+ A3)/3 N (B1 + B2 + B3)/3 N (ab1 + ab2 + ab3)/3 N
+ A4)/3 N (B1 + B2 + B4)/3 N (ab1 + ab2 + ab4)/2 N
+ A4)/3 N (B1 + B3 + B4)/3 N (ab1 + ab3 + ab4)/3 N
+ A4)/3 N (B2 + B3 + B4)/3 N (ab2 + ab3 + ab4)/3 N
A3 + A4)/4 N (B1 + B2 + B3 + B4)/4 N (ab1 + ab2 + ab3 + ab4)/4 N
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Oracle Clinical Version 4.6 software (Oracle, Redwood
Shores, CA, USA) will be used for clinical data management.
Discussion
TCM syndrome differentiation is the key to understand-
ing the condition or disease and also to choosing the
best means of treatment according to traditional Chinese
beliefs. It is also held that the efficacy of TCM is most
obviously observed in alleviating or improving the char-
acteristic symptoms of patients diagnosed with the cor-
responding TCM syndrome.
We will conduct a multicenter, randomized, double-
blind, double-dummy trial to compare the effectiveness
of two Chinese patent drugs, namely, QSYQ and TXL,
for angina patients with qi deficiency and blood stasis
syndrome.
The study features the grouping of patients with varied
treatment needs, the integration of PIO and PRO in effi-
cacy assessment and the use of CA in identifying the
most significant correlations between different symptom
combinations and treatment outcomes. The ultimate
goal of this exploratory study is to establish a method-
ology for the precise identification of the characteristic
indications for which a Chinese patent drug is most ef-
fective, and thus differentiation from other drugs used
for similar clinical indications in clinical use.
Strengths and limitations
Strengths
The following are the potential strengths of our study
protocol:
1. Evaluation and interpretation of the therapeutic
effects of Chinese patent medicine from the patient’s
own perspective
2. Highlighting of individualized evaluation of Chinese
patent medicine.
3. Analysis of the curative effects of Chinese patent
medicine on single- or multiple-symptom
combinations
4. Visualized display of the correspondence between
the drug’s efficacy and a specific indication or group
of indications
5. Comparison of the therapeutic effects of Chinese
patent drugs with other drugs used for similar clinical
Limitations
The proposed methodology needs to be tested for practi-
cality and feasibility in practice.
Implications
By comparing the effects of two kinds of Chinese patent
medicine on angina symptom improvement, we aim toestablish an innovative evaluation methodology that can
facilitate the widespread and rational use of Chinese
patent drugs by practitioners of TCM and Western
medicine.
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